Active ingredient
- talimogene laherparepvec
Legal Category
POM: Prescription only medicine
POM: Prescription only medicine
This brochure contains important safety information you should know before and during IMLYGIC treatment. Please read this information carefully before and after each treatment. Please also read the IMLYGIC Package Leaflet. To request a copy of this guide, please contact Amgen Medical Information on +44 (0) 1223 436441
This IMLYGIC patient alert card includes contact details of the IMLYGIC prescriber, treatment start date, IMLYGIC batch number and information on the potential development of herpetic lesions and the importance of reporting ADRs. To request a copy of the patient card, please contact Amgen Medical Information on +44 (0) 1223 436441
This educational brochure contains important information regarding the risks of transmission and herpetic complications, and safe use and handling of IMLYGIC.This brochure does not contain a comprehensive description of the risks associated with IMLYGIC. Please read the current Summary of Product Characteristics (SmPC) for IMLYGIC. To request a copy of the brochure, please contact Amgen Medical Information on +44 (0) 1223 436441
For Healthcare Professionals
If you would like to make a comment or send us feedback on this material, click here.
216 Cambridge Science Park, Milton Road, Cambridge, CB4 0WA, UK
+44 (0)1223 426 314
+44 (0)1223 426 314
+44 (0)1223 420 305
+44 (0)1223 436 441
+44 (0)808 0100 321